# NCT03805594 (NCT03805594)

> 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

No report yet. It can be ordered.

- Drugs tested: 177Lu-PSMA-617 plus pembrolizumab
- Indication: metastatic castration-resistant prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03805594
- Phase: PHASE1
- Status: COMPLETED
- Sponsor: University of California, San Francisco
- Conditions: Castration Levels of Testosterone; Castration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma; Prostate Adenocarcinoma; Stage IV Prostate Cancer; Stage IVA Prostate Cancer; Stage IVB Prostate Cancer
- Interventions: Lutetium Lu 177-PSMA-617; Pembrolizumab
- Enrollment: 43
- Primary outcome: Number of Reported Dose Limiting Toxicities (DLT) (Part A Only)
- Primary outcome: Objective Response Rate (ORR) (Part B Only)

## Indexed commentary on NCT03805594 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct03805594